Stocks and Investing Stocks and Investing
Thu, April 13, 2023

Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $27 on, Apr 13th, 2023


Published on 2024-10-28 02:44:19 - WOPRAI, Mani Foroohar
  Print publication without navigation


Mani Foroohar of SVB Securities, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $25 to $27 on, Apr 13th, 2023.

Mani has made no other calls on BBIO in the last 4 months.



There are 4 other peers that have a rating on BBIO. Out of the 4 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Mani


  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $23 on, Tuesday, March 7th, 2023
  • Dane Leone of "Raymond James" Maintained at Buy with Increased Target to $29 on, Tuesday, March 7th, 2023
  • Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $28 on, Tuesday, March 7th, 2023
  • Tyler Van Buren of "Cowen & Co." Initiated at Buy on, Monday, February 6th, 2023

Contributing Sources
    D885FD0B-4D59-419D-81DE-3DF4BF5AB503
  • support@woprai.com